Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Politics & Policy

Medicare bill aims to block drugmakers from misclassifying drugs

December 4, 2018 11:28 PM UTC

A bipartisan bill introduced Tuesday by members of the Senate Finance Committee would prevent drugmakers from profiting by misclassifying drugs to Medicare as generics.

The bill is in response to a lawsuit against Mylan N.V. (NASDAQ:MYL) for misclassifying its EpiPen as a generic in order to shrink its required Medicaid rebate. The company settled the suit in 2016 with an agreement to pay the government $465 million (see "Mylan Inflammation News")...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Mylan N.V.